Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...
Following completion of the 2025 re-assay program, the Berg database contains 26,797 unique assay intervals, of which 22,138 samples, or 82.6%, now include gold and silver analyses. This represents a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback